Compare GHC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GHC | SRRK |
|---|---|---|
| Founded | 1877 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.5B |
| IPO Year | 1994 | 2018 |
| Metric | GHC | SRRK |
|---|---|---|
| Price | $1,163.55 | $52.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $56.17 |
| AVG Volume (30 Days) | 15.2K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 66.47 | N/A |
| Revenue | ★ $2,932,099,000.00 | N/A |
| Revenue This Year | $7.73 | N/A |
| Revenue Next Year | $4.37 | $534.24 |
| P/E Ratio | $17.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $882.21 | $27.07 |
| 52 Week High | $1,224.76 | $52.19 |
| Indicator | GHC | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 67.81 |
| Support Level | $1,028.08 | $45.46 |
| Resistance Level | $1,197.21 | N/A |
| Average True Range (ATR) | 32.50 | 2.19 |
| MACD | 2.12 | 0.82 |
| Stochastic Oscillator | 70.39 | 89.41 |
Graham Holdings Company is a diversified holding company with operations spanning educational services, television broadcasting, healthcare, manufacturing, automotive dealerships, and other businesses. The Company's education activities are conducted through Kaplan, whose services include academic preparation programs for international students, English-language programs, exam preparation, and career and academic advisement. These services are provided to students, schools, and colleges, both domestically and outside the United States. It operates through seven reportable segments: Kaplan International, Kaplan Higher Education, Kaplan Supplemental Education, Television Broadcasting, CSI, Manufacturing and Automotive, with key revenue coming from the Education and Automotive segments.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.